Cytokinetics Inc (CYTK)vsNovartis AG ADR (NVS)
CYTK
Cytokinetics Inc
$53.69
-3.35%
HEALTHCARE · Cap: $8.55B
NVS
Novartis AG ADR
$162.55
+0.38%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 84670% more annual revenue ($57.36B vs $67.67M). NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).
CYTK
Avoid22
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-36.9%
Fair Value
$39.21
Current Price
$53.69
$14.48 premium
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$162.55
$66.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -572.0% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CYTK
The strongest argument for CYTK centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : CYTK
The primary concerns for CYTK are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.47 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (48/100 vs 22/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cytokinetics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?